会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • USE OF HTRA1 FOR EARLY DETECTION OF COLORECTAL CANCER
    • 使用HTRA1早期检测彩色癌
    • WO2017060840A1
    • 2017-04-13
    • PCT/IB2016/055979
    • 2016-10-06
    • UNIVERSITÀ DEGLI STUDI DELL'AQUILA
    • ALTOBELLI, Emma
    • G01N33/574
    • G01N33/57419G01N2333/96425
    • The invention relates to a novel test for the early diagnosis of colorectal cancer (CRC),. The test measures the expression decrease of HtrA1 protein in plasma samples. Its application implies either the use of HtrA1 alone or in combination with the immunochemical fecal occult blood test (iFOBT). The latter application is called "combined test". The new test offers the advantage of affording greater sensitivity than the most reliable available fecal occult blood test (FOBT). It may be hypothesized that the test could be used for routine population-based CRC screening, either alone or combined, before patients who are positive for fecal occult blood are referred for colonoscopy.
    • 本发明涉及一种用于结直肠癌(CRC)早期诊断的新型检测方法。 该测试测量血浆样品中HtrA1蛋白的表达降低。 其应用意味着单独使用HtrA1或与免疫化学粪便潜血试验(iFOBT)组合使用。 后一种应用被称为“组合测试”。 新测试提供了比最可靠的可靠的粪便潜血试验(FOBT)提供更大的灵敏度的优点。 可以假设,在将粪便潜血阳性的患者称为结肠镜检查之前,该检测可以单独使用或组合用于常规基于人群的CRC筛查。